Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARECEC: Cetuximab Plus Chemotherapy for High Risk Resectable Colorectal Liver Metastasis
NCT03031444Phase 3Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2016
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Disease Free Survival at 60 months. Started Jan 2016; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03031444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031444.